Compare 10X Genomics Inc (TXG) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? 10X Genomics Inc trades at $79 (market cap $10.07B), while Vanguard Total International Stock Index Fund ETF trades at $84.71 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 66.1× 10X Genomics Inc's market cap, and 10X Genomics Inc is more actively traded (5,657,286 versus 4,864,744). Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| TXG | VXUS | |
|---|---|---|
Market Cap | $10.07B | $665.70B |
Volume | 5,657,286 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $97.74 | $88.41 |
52-Week Low | $11.48 | $72.17 |
Typical Hold Time | 92 Days | 55 Days |
Enterprise Value | $9.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
VXUS trades at $84.78, down 1.19% with a bearish technical signal from moving averages. The ETF provides broad international stock exposure outside the U.S., with institutional buying interest noted in recent SEC filings. Technical indicators show neutral oscillators but bearish momentum signals from ADX readings.
The fund offers diversification benefits as a core international holding, though recent performance faces headwinds. Key risks include currency fluctuations and emerging market volatility. Long-term outlook remains positive for global equity exposure, supported by Vanguard's low-cost structure and comprehensive market coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
